Troglitazone-d4

• UNSPSC Description:

  Troglitazone-d4 is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

• Target Antigen:

  Apoptosis; Autophagy; Ferroptosis; Isotope-Labeled Compounds; PPAR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Others;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1SC(CC2=C([2H])C([2H])=C(C([2H])=C2[2H])OCC3(C)OC4=C(CC3)C(C)=C(O)C(C)=C4C)C(N1)=O

• Molecular Weight:

  445.56

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Fujita M, et al. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. J Exp Clin Cancer Res. 2017 Jul 3;36(1):91.|[3]Nazim UM, et al. PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget. 2017 Apr 18;8(16):26819-26831.|[4]Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43(4):527-50.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2749370-85-0